Genetic and cellular studies of familial hemophagocytic lymphohistiocytosis
Author: Rudd, Eva
Date: 2007-12-14
Location: Skandiasalen, Astrid Lindgrens Barnsjukhus, Karolinska Univeristetsjukhuset, Solna
Time: 09.00
Department: Institutionen för kvinnors och barns hälsa / Department of Women's and Children's Health
View/ Open:
Thesis (383.1Kb)
Abstract
Familial hemophagocytic lymphohistiocytosis (FHL) is a rare autosomal recessive and genetically heterogeneous disorder of immune dysregulation with an incidence of 1/50000 live births that is inevitably fatal without appropriate treatment. The disease is characterized by fever, hepatosplenomegaly, cytopenias, hyperferritinemia, hypertriglyceridemia, hypofibrinogenemia and, sometimes, hemophagocytosis in bone marrow and/or other organs such as liver, spleen or lymph nodes.
Three genes have so far been linked to the disease: PRF1, UNC13D and STX11. In this thesis the mutational spectrum and clinical implications of UNC13D and STX11 mutations in a well characterized cohort of patients were studied. Moreover, functional cellular studies with focus on natural killer (NK) cell activity and cytotoxic lymphocyte degranulation was performed in patients with mutations affecting these three genes. In addition, genotype-phenotype correlations in a large cohort of patients was studied.
The frequency of bi-allelic STX11 mutations in our cohort of PRF1-negative families was 14%. Some affected patients had a remarkably less severe disease course than most FHL patients, including long periods of remission without therapy. However, a few patients developed secondary MDS/AML. Although this could be attributed to the treatment provided including etoposide, it is also possible that mutations affecting cytotoxic functions may affect the surveillance of transformed cells (paper I).
The localization and function of the protein syntaxin-11 encoded by the gene STX11 was previously unknown. We report that the protein is expressed in cytotoxic T cells as well as NK cells, and that NK cells from patients with biallelic STX11 mutations fail to degranulate when encountering susceptible target cells. The same pattern is seen in patients carrying UNC13D mutations whereas patients carrying PRF1 mutations have a normal degranulation pattern. Notably, when stimulated with IL-2, syntaxin-11 deficient cells regained their cytotoxic capacity and this was also observed in a patient carrying a bi-allelic UNC13D mutation (paper II).
We identified six different UNC13D mutations affecting altogether 9/38 individuals (24%) in 6/34 (18%) unrelated PRF1/STX11-negative families. Four novel mutations were revealed. The age at onset varied from birth to 14 years in the patients carrying bi-allelic UNC13D mutations, high-lighting that FHL should be considered not only in infants but also in adolescents, and possibly young adults, presenting with fever, splenomegaly, cytopenia, hyperferritinemia, and/or CNS symptoms (paper III).
Since hemophagocytic lymphohistiocytosis (HLH) is a heterogeneous disease with regard to genotype and phenotype, we studied 76 patients with HLH in order to search for genotype-phenotype correlations. Patients carrying PRF1 mutations had significantly higher risk of early onset (age <6 months) compared with patients carrying mutations in STX11 [adjusted odds ratio 8.23 (95% CI=1.20-56.40), p=0.035]. Moreover, patients with STX11 mutations had a decreased risk of pathological CSF at diagnosis compared to patients without any known biallelic mutation [adjusted odds ratio 26.37 (95% CI=1.90-366.81), p=0.015] (paper IV).
Three genes have so far been linked to the disease: PRF1, UNC13D and STX11. In this thesis the mutational spectrum and clinical implications of UNC13D and STX11 mutations in a well characterized cohort of patients were studied. Moreover, functional cellular studies with focus on natural killer (NK) cell activity and cytotoxic lymphocyte degranulation was performed in patients with mutations affecting these three genes. In addition, genotype-phenotype correlations in a large cohort of patients was studied.
The frequency of bi-allelic STX11 mutations in our cohort of PRF1-negative families was 14%. Some affected patients had a remarkably less severe disease course than most FHL patients, including long periods of remission without therapy. However, a few patients developed secondary MDS/AML. Although this could be attributed to the treatment provided including etoposide, it is also possible that mutations affecting cytotoxic functions may affect the surveillance of transformed cells (paper I).
The localization and function of the protein syntaxin-11 encoded by the gene STX11 was previously unknown. We report that the protein is expressed in cytotoxic T cells as well as NK cells, and that NK cells from patients with biallelic STX11 mutations fail to degranulate when encountering susceptible target cells. The same pattern is seen in patients carrying UNC13D mutations whereas patients carrying PRF1 mutations have a normal degranulation pattern. Notably, when stimulated with IL-2, syntaxin-11 deficient cells regained their cytotoxic capacity and this was also observed in a patient carrying a bi-allelic UNC13D mutation (paper II).
We identified six different UNC13D mutations affecting altogether 9/38 individuals (24%) in 6/34 (18%) unrelated PRF1/STX11-negative families. Four novel mutations were revealed. The age at onset varied from birth to 14 years in the patients carrying bi-allelic UNC13D mutations, high-lighting that FHL should be considered not only in infants but also in adolescents, and possibly young adults, presenting with fever, splenomegaly, cytopenia, hyperferritinemia, and/or CNS symptoms (paper III).
Since hemophagocytic lymphohistiocytosis (HLH) is a heterogeneous disease with regard to genotype and phenotype, we studied 76 patients with HLH in order to search for genotype-phenotype correlations. Patients carrying PRF1 mutations had significantly higher risk of early onset (age <6 months) compared with patients carrying mutations in STX11 [adjusted odds ratio 8.23 (95% CI=1.20-56.40), p=0.035]. Moreover, patients with STX11 mutations had a decreased risk of pathological CSF at diagnosis compared to patients without any known biallelic mutation [adjusted odds ratio 26.37 (95% CI=1.90-366.81), p=0.015] (paper IV).
List of papers:
I. Rudd E, Göransdotter Ericson K, Zheng C, Uysal Z, Ozkan A, Gürgey A, Fadeel B, Nordenskjöld M, Henter JI (2006). Spectrum and clinical implications of syntaxin 11 gene mutations in familial haemophagocytic lymphohistiocytosis: association with disease-free remissions and haematopoietic malignancies. J Med Genet. 43(4): e14
Pubmed
II. Bryceson YT, Rudd E, Zheng C, Edner J, Ma D, Wood SM, Bechensteen AG, Boelens JJ, Celkan T, Farah RA, Hultenby K, Winiarski J, Roche PA, Nordenskjöld M, Henter JI, Long EO, Ljunggren HG (2007). Defective cytotoxic lymphocyte degranulation in syntaxin-11 deficient familial hemophagocytic lymphohistiocytosis 4 (FHL4) patients. Blood. 110(6): 1906-15. Epub 2007 May 24
Pubmed
III. Rudd E, Bryceson YT, Zheng C, Edner J, Wood SM, Ramme K, Gavhed S, Gürgey A, Hellebostad M, Bechensteen A, Ljunggren HG, Fadeel B, Nordenskjold M, Henter JI (2007). Spectrum, and clinical and functional implications of UNC13D mutations in familial hemophagocytic lymphohistiocytosis. J Med Genet. Nov 9: Epub ahead of print
Pubmed
IV. Horne AC, Ramme KG, Rudd E, Zheng C, Wali Y, al-Lamki Z, Gürgey A, Yalman N, Nordenskjöld M, Henter J-I (2007). Characterization of PRF1, STX11 and UNC13D genotype-phenotype correlations in familial hemophagocytic lymphohistiocytosis. [Submitted]
I. Rudd E, Göransdotter Ericson K, Zheng C, Uysal Z, Ozkan A, Gürgey A, Fadeel B, Nordenskjöld M, Henter JI (2006). Spectrum and clinical implications of syntaxin 11 gene mutations in familial haemophagocytic lymphohistiocytosis: association with disease-free remissions and haematopoietic malignancies. J Med Genet. 43(4): e14
Pubmed
II. Bryceson YT, Rudd E, Zheng C, Edner J, Ma D, Wood SM, Bechensteen AG, Boelens JJ, Celkan T, Farah RA, Hultenby K, Winiarski J, Roche PA, Nordenskjöld M, Henter JI, Long EO, Ljunggren HG (2007). Defective cytotoxic lymphocyte degranulation in syntaxin-11 deficient familial hemophagocytic lymphohistiocytosis 4 (FHL4) patients. Blood. 110(6): 1906-15. Epub 2007 May 24
Pubmed
III. Rudd E, Bryceson YT, Zheng C, Edner J, Wood SM, Ramme K, Gavhed S, Gürgey A, Hellebostad M, Bechensteen A, Ljunggren HG, Fadeel B, Nordenskjold M, Henter JI (2007). Spectrum, and clinical and functional implications of UNC13D mutations in familial hemophagocytic lymphohistiocytosis. J Med Genet. Nov 9: Epub ahead of print
Pubmed
IV. Horne AC, Ramme KG, Rudd E, Zheng C, Wali Y, al-Lamki Z, Gürgey A, Yalman N, Nordenskjöld M, Henter J-I (2007). Characterization of PRF1, STX11 and UNC13D genotype-phenotype correlations in familial hemophagocytic lymphohistiocytosis. [Submitted]
Issue date: 2007-11-23
Rights:
Publication year: 2007
ISBN: 978-91-7357-348-1
Statistics
Total Visits
Views | |
---|---|
Genetic ...(legacy) | 689 |
Genetic ... | 127 |
Total Visits Per Month
September 2023 | October 2023 | November 2023 | December 2023 | January 2024 | February 2024 | March 2024 | |
---|---|---|---|---|---|---|---|
Genetic ... | 1 | 1 | 4 | 1 | 1 | 0 | 0 |
File Visits
Views | |
---|---|
thesis.pdf(legacy) | 357 |
thesis.pdf | 118 |
thesis.pdf.txt(legacy) | 2 |
Top country views
Views | |
---|---|
United States | 318 |
Sweden | 91 |
China | 67 |
Germany | 58 |
South Korea | 14 |
Finland | 11 |
United Kingdom | 10 |
Russia | 9 |
India | 8 |
Denmark | 6 |
Top cities views
Views | |
---|---|
Beijing | 27 |
Sunnyvale | 26 |
Romeo | 21 |
Kiez | 19 |
Seoul | 14 |
Stockholm | 11 |
London | 7 |
Ashburn | 6 |
Ballerup | 6 |
Dublin | 5 |